Boehringer Ingelheim in the news

Boehringer Ingelheim launched a new quarterable PREVICOX chewable tablet for dogs, allowing precise dosing and offering sustainability benefits.

Boehringer Ingelheim, a German pharmaceutical company, successfully attracts and retains international talent despite its remote location.

The Boehringer Ingelheim family is now Germany's richest, with 66.7 billion Euros, dethroning Lidl founder Dieter Schwarz.

The shareholder families of the pharmaceutical company Boehringer Ingelheim are ranked as the wealthiest Germans in 2026, surpassing Lidl founder Dieter Schwarz.

Boehringer Ingelheim partnered with SLR Consulting to transform energy systems across its sites, aiming for a 58.9% reduction in Scope 1 and 2 emissions by 2030 and significant cost optimization.

The UK patent trial for the drug Jardiance began, focusing on insufficient biological data and contested testing evidence.

Boehringer Ingelheim warns about a potential shortage of new cancer drugs in Europe, with pharmaceutical executives predicting patients may not access innovative medicines due to investment cuts.

Boehringer Ingelheim's Jen Roberts details strategic dry-off practices, mastitis management, and the importance of employee training for dairy producers.

Boehringer Ingelheim is investing €500 million by 2026 into sustainability and health partnerships, primarily through its BISE Fund, to support healthcare start-ups and expand access to health solutions globally.

Boehringer Ingelheim heavily invests in R&D and needs strong returns from its pipeline to compensate for patent expirations and justify large investments, while its private ownership makes financial valuation challenging.

The shareholder families of Boehringer Ingelheim have become the richest Germans in 2026, surpassing Lidl founder Dieter Schwarz, according to Manager Magazin.

The Delaware Chancery Court allowed Boehringer Ingelheim to proceed with discovery in a trade secret case against United Therapeutics but denied a rapid forensic discovery request due to the company's delay.

Boehringer Ingelheim announced positive Phase III SYNCHRONIZE-2 trial results for survodutide, showing significant weight loss and improved glycemic control in individuals with obesity and type 2 diabetes.

Boehringer Ingelheim collaborates with social innovators like Soydoy to support community health and employee purpose, developing tools like the Olana wellbeing platform, facilitated by partners like Ashoka.

The Boehringer Ingelheim shareholder family leads the 2026 Manager Magazin's list of the richest Germans with 66.7 billion Euros, followed by Dieter Schwarz and the Merck family, marking Boehringer Ingelheim's debut on the list due to prior agreements.

The Boehringer Ingelheim family became Germany's wealthiest in 2026 with 66.7 billion Euros, surpassing Dieter Schwarz.

Boehringer Ingelheim and Dr. Reddy's Laboratories are going to court over the legalities of 'skinny label' generic drugs and their non-patented uses.

Boehringer Ingelheim's researcher Peter Nickolaus dedicated two decades to developing the lung medication Jascayd, with its study results presented in Fall 2021.

Boehringer Ingelheim's survodutide achieved up to 13.1% weight reduction and improved cardiometabolic health in adults with type 2 diabetes in a Phase III trial.

Boehringer Ingelheim, a leading global pharmaceutical company, maintains its independence as a family-owned business and has no plans to go public, as explained by CEO Shashank Deshpande.